The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline activity, and anticipated regulatory ...

Researchers have developed a new gene-editing platform that will enable safer and more effective T cell–based immunotherapies ...

We are investigating so-called anti-CRISPRs: proteins or other molecules that phages use to inhibit CRISPR. A bacterium that has CRISPR might be able to stop a phage from infecting. But if the phage ...

CRISPR Therapeutics could stage a comeback thanks to clinical and commercial progress. There are many promising corporations ...

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...

A recent study involving researchers from the University of Basel reveals that slowing down the intracellular transport of ...

This in vivo targeted lipid nanoparticle anti-CD19 CAR-T therapy candidate is currently in Phase 1 development. Additionally, AbbVie will acquire Capstan's proprietary tLNP platform technology ...

Scientists unveil novel anti-CRISPR protein mechanism for precise control of genome editing technologies.

Innovative synthetic biology techniques are revolutionizing microbiota-based therapies, enhancing microbial functions for improved health and disease treatment.

Two anti-CRISPR proteins can "turn off" Cas3, paving the way toward safer and better-controlled CRISPR applications.

Finally, the Zhang team provided key proof-of-concept evidence that each of these anti-CRISPR protein can serve as an off-switch for CRISPR-Cas3 in human cells.

Bacteria have CRISPR-Cas so the phages have developed anti-CRISPRs, which enables them to block the immune complexes of the bacteria.